PMVP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PMVP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PMV Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
PMV Pharmaceuticals Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.GuruFocus does not calculate PMV Pharmaceuticals's interest coverage with the available data. As of today, PMV Pharmaceuticals's Altman Z-Score is 0.00.
For the Biotechnology subindustry, PMV Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, PMV Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where PMV Pharmaceuticals's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
PMV Pharmaceuticals's Interest Expense for the months ended in Sep. 2024 was $0.00 Mil. Its Operating Income for the months ended in Sep. 2024 was $-21.89 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $12.02 Mil.
PMV Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is
GuruFocus does not calculate PMV Pharmaceuticals's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. PMV Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
PMV Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Sep. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (1.243 | + | 12.024) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
PMV Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PMV Pharmaceuticals (NAS:PMVP) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
PMV Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Thank you for viewing the detailed overview of PMV Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Deepika Jalota | officer: SVP, Regulatory Affairs and QA | C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512 |
Orbimed Advisors Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Leila Alland | officer: Chief Medical Officer | C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512 |
Carol Giltner Gallagher | director | C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Orbimed Capital Gp V Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Orbimed Genesis Gp Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Kirsten Flowers | director | C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130 |
Thilo Schroeder | director, 10 percent owner | C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001 |
Arnold J Levine | director | C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015 |
Winston Kung | officer: COO, CFO | C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512 |
David Henry Mack | director, officer: President and CEO | ONE EMBARCADERO CENTER, SUITE 3700, SAN FRANCISCO CA 94111 |
Euclidean Capital Llc | 10 percent owner | 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010 |
James H Simons | 10 percent owner | RENAISSANCE TECHNOLOGIES LLC, 800 THIRD AVE, NEW YORK NY 10022 |
Greenland A Llc | 10 percent owner | C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010 |
Greenland Fp Llc | 10 percent owner | C/O EUCLIDEAN CAPITAL LLC, 160 FIFTH AVE, 9TH FL, NEW YORK NY 10010 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-09-2022
By sperokesalga sperokesalga • 05-10-2023
By GuruFocus Research • 11-09-2023
By GuruFocus News • 11-14-2024
By Marketwired • 10-11-2023
By sperokesalga sperokesalga • 06-06-2023
By GuruFocus Research • 02-08-2024
By Marketwired • 10-12-2023
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 02-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.